Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Orchard Therapeutics plc (ORTX)
|
Add to portfolio |
|
|
|
| Price: |
$1.41
| | Metrics |
| OS: |
227.2
|
M
| |
|
|
| Market cap: |
$320
|
M
| |
-44
|
% ROIC
|
|
Net cash:
|
$10.4
|
M
| |
$0.05
|
per share
|
|
EV:
|
$310
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($63.3)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 22.7 | 1.7 | 2.6 | 2.5 | 2.1 | 0.0 | 0.0 |
| Revenue growth | 1252.5% | -35.5% | 3.3% | 21.1% | | | |
| Cost of goods sold | 6.8 | 0.2 | 0.9 | 0.8 | 0.4 | 0.0 | 0.0 |
| Gross profit | 15.9 | 1.4 | 1.7 | 1.7 | 1.7 | 0.0 | 0.0 |
| Gross margin | 70.1% | 86.5% | 67.0% | 68.0% | 79.7% | | |
| Selling, general and administrative | 143.0 | 141.9 | 65.0 | 57.2 | 31.4 | 6.0 | 3.0 |
| Research and development | | | 93.7 | 117.4 | 205.3 | 32.5 | 16.2 |
| EBITA | -178.7 | -146.9 | -157.0 | -172.9 | -235.0 | -38.5 | -19.2 |
| EBITA margin | -788.7% | -8768.9% | -6049.2% | -6879.1% | -11321.3% | | |
| Amortization of intangibles | 0.3 | 0.2 | | | | | |
| EBIT | -179.0 | -147.1 | -157.0 | -172.9 | -235.0 | -38.5 | -19.2 |
| EBIT margin | -790.0% | -8780.8% | -6049.2% | -6879.1% | -11321.3% | | |
| Pre-tax income | -153.0 | -143.8 | -152.7 | -165.7 | -229.5 | -39.7 | -19.1 |
| Income taxes | -2.4 | 0.8 | -0.7 | -2.2 | 1.0 | 0.1 | 0.0 |
| Tax rate | 1.6% | | 0.5% | 1.4% | | | 0.1% |
| Net income | -150.7 | -144.6 | -152.0 | -163.4 | -230.5 | -39.7 | -19.1 |
| Net margin | -665.0% | -8631.9% | -5856.6% | -6503.1% | -11102.8% | | |
| |
| Diluted EPS | ($1.18) | ($1.17) | ($1.53) | ($1.75) | ($10.22) | ($4.48) | ($2.69) |
| Shares outstanding (diluted) | 128.0 | 124.0 | 99.4 | 93.2 | 22.6 | 8.9 | 7.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|